U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

Core Viewpoint - The FDA has approved NUZOLVENCE® (zoliflodacin), a first-in-class oral medication for treating uncomplicated urogenital gonorrhea in adults and pediatric patients aged 12 and older weighing at least 35 kg [1] Company Summary - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is responsible for the development and announcement of NUZOLVENCE [1] - The development of NUZOLVENCE was part of a private, not-for-profit collaboration [1] Industry Summary - The approval of NUZOLVENCE represents a significant advancement in the treatment options available for uncomplicated urogenital gonorrhea [1]